Enhanced Seasonal Influenza Vaccine Targeting Shared and Variable Viral Antigens
Official title: Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens
Funded at Orlance, INC. · NIH-11532352 · Data updated 2026-11-12
A new DNA-based influenza vaccine approach aims to provide both precise protection against circulating strains and broader defense against unexpected strains.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Orlance, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 8, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,000,000 |
| NIH project number | 4R44AI186932-02 |
| Project ID | NIH-11532352 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals at risk for seasonal influenza seeking improved and longer-lasting protection may be suitable for future trials.
✕Less likely to help
People seeking short-term, strictly matched seasonal vaccines without interest in broader protection may not directly benefit at early stages.
What this research studies
This project combines a seasonal influenza DNA vaccine that can be produced close to flu season with a universal DNA vaccine component designed to protect against a wider range of strains. The approach focuses on inducing broad antibody responses to conserved antigens while maintaining strain-specific matching. Researchers will test how well this combined vaccine stimulates immune responses and reduces disease in preclinical models and early clinical settings, with attention to vaccine production timing and cold-chain considerations. If successful, this strategy could lead to more reliable protection across flu seasons and potential pandemic threats.
Why it matters
Potential benefit: If successful, patients could receive more reliable protection against flu during each season and better defense against newly emerging strains.
How similar studies have gone: Previous work on universal and matched influenza vaccine concepts has shown promise in eliciting broader immune responses, though combined DNA-based strategies are relatively novel.
Where this research is happening
-
Orlance, INC.
Seattle, United States Active
Researchers
- Principal investigator: Bagley, Kenneth C — Orlance, INC.
- Study coordinator: Bagley, Kenneth C
Related research
Other NIH-funded projects on the same topics.
-
Creating vaccines for influenza and other infectious diseases
This study is all about creating new vaccines to help protect people from the flu and other infections, so patients can look forward to better options for staying healthy.
-
Creating vaccines for human trials against influenza and other infectious diseases
This study is working on creating new vaccines to help protect people from flu and other infectious diseases, including those that could be used in harmful situations, so that everyone can have safer and more effective options to stay healthy.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Surveillance and preparedness for flu and other respiratory pathogens in Kenya
A US-based research grant aims to improve how Kenya detects and prepares for influenza and other respiratory diseases to protect people there and global health.
-
How the immune system responds to flu shots and flu infection
This project looks at how adults' immune systems react after flu shots or when they catch the flu to find why some people get better protection than others.
-
Influenza and SARS-CoV-2 in pregnancy in India
A study following pregnant women in India to track how flu and COVID viruses affect mothers and newborns.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.